How should feline antiemetic doses be checked?

Check formulation, route, amount per administration, interval and whether units are mg/kg or mg/cat. Published regimens are references; a veterinarian adjusts for disease and other medicines.

Can daily Cerenia be associated with appetite loss in some cats?

It is a possible adverse drug reaction. A 13–17-hour feline half-life, accumulation and anorexia reports exist, but they do not establish an oral incidence or prove accumulation caused an individual cat’s signs. Review medication and food records with your veterinarian.

Does maropitant block mirtazapine’s appetite effect?

The literature reviewed did not establish direct blockade in cats. Possible drug-associated appetite reduction and proof of a direct interaction are different questions.

Does tolerating treatment for weeks establish long-term safety?

Short studies cannot establish safety over months or years. Reassess benefit, intake, weight, behaviour, underlying disease and appropriate laboratory monitoring with your veterinarian.

Feline Antiemetics: Maropitant, Ondansetron & Metoclopramide

14분 read 고양이연구소 2026-09-18 처방식 및 질병별 식단 관리

Stopping vomiting and restoring comfortable eating are different outcomes. Antiemetics support treatment of the underlying illness and nutritional care. This guide covers maropitant, ondansetron, metoclopramide and adjunctive mirtazapine, separating published doses, short-term adverse effects and limits of longer-term evidence.

⚠️

These are literature references for discussing a prescription, not instructions for self-treatment. Formulation, route, disease, kidney/liver function and other medicines affect dosing. Do not start, increase or change intervals yourself. US authorisations may differ from local product labels.

Quick links

Dose and route comparison
Maropitant
Ondansetron
Metoclopramide
Mirtazapine
Care example
Monitoring
Sources

1. Reference doses by drug and formulation

mg/kg means per kilogram; mg/cat means per cat. Intermittent doses below are per administration; the infusion dose is a 24-hour total. Milligrams measure drug amount, not liquid volume (mL). Injections and infusions require veterinary administration.

Drug/formulation	Published regimen	Evidence and limits
Maropitant injection	1 mg/kg SC or IV every 24 h	US Cerenia label: vomiting in cats ≥4 months, up to 5 consecutive days; IV over 1–2 minutes. [2]
Oral maropitant	1 mg/kg every 24 h	ISFM consensus; feline oral use is extra-label in the US. Do not use the canine motion-sickness regimen. [1][2]
Ondansetron	0.1–1 mg/kg every 6–12 h	ISFM range across oral, SC, IM and slow IV routes; higher end orally. Routes are not interchangeable prescriptions. [1]
Intermittent metoclopramide	0.25–0.5 mg/kg oral, SC, IM or IV every 8 h	ISFM consensus. Confirm the indication. [1]
Metoclopramide infusion	1–2 mg/kg/24 h IV	Total spread over 24 hours, not a bolus or hourly dose. [1]
Oral mirtazapine — appetite/antiemetic adjunct	General reference: about 2 mg/cat every 24 h Stable CKD trial: 1.88 mg/cat every 48 h for 3 weeks	Consensus versus a small clinical trial; kidney/liver disease may require interval adjustment. [1][8]
Mirataz 2% transdermal mirtazapine	2 mg/cat on inner ear skin every 24 h for 14 days	US weight-gain indication in cats with weight loss. Not interchangeable with oral or differently compounded products. [9]

SC = subcutaneous; IV = intravenous; IM = intramuscular. Read the evidence column: licensed regimens, consensus recommendations and trial doses are different. This is not a table for choosing the largest dose.

2. Maropitant — Cerenia

This NK-1 antagonist suppresses vomiting signals. Less vomiting does not establish that nausea or the underlying disease has resolved.

Feline trial

A placebo-controlled CKD trial used 4 mg/cat orally daily for 2 weeks. Vomiting decreased, but appetite, activity and weight did not improve significantly. This fixed trial dose is not a universal prescription for cats of every weight. [3]

Short-term adverse effects

Injection pain is prominent. In the US feline injection study, moderate and significant injection reactions occurred in 22.6% and 11.3% of 133 treated cats. Anorexia occurred in 1/133 (0.8%) versus 0/62 controls and appears in postmarketing reports; lethargy and salivation were also reported; hypersensitivity is a concern. These are observed injection-study events, not oral adverse-effect rates or proof of causation for every event. [2]

Half-life and repeated dosing

Hickman et al. (2008) reported a 13–17-hour terminal half-life after single oral, SC and IV doses in cats. [12] The Cerenia label documents accumulation with 1 mg/kg SC daily for five days. [2]

Longer-term limits

The two-week CKD trial found no apparent drug adverse effects; it does not establish safety over months or years. [3] Repeated dosing increases exposure and hepatic metabolism warrants caution in liver disease. Accumulation alone does not prove toxicity or justify alternate-day dosing. Reassess intake, weight, activity, other medicines and liver testing where indicated. [2]

An uncontrolled, open-label dermatology pilot used 2 mg/kg orally daily for 28 days in 12 cats; two salivated. No blood testing was performed, and the study cannot exclude appetite suppression or longer-term organ injury. This extra-label research regimen is not a recommended vomiting dose. [13]

3. Ondansetron

This 5-HT3 antagonist requires attention to both route and interval.

Route matters

In six healthy cats given 2 mg/cat by each route in a crossover pharmacokinetic study, average bioavailability was 32% orally and 75% subcutaneously; SC exposure lasted longer. This measured drug concentrations, not long-term clinical effectiveness or safety. [4]

Short-term precautions

Constipation/GI effects and rare hypersensitivity are recognised concerns. [1] QT prolongation, arrhythmias and serotonin-syndrome warnings come from human prescribing information; feline incidence is not established. A veterinarian should assess cardiac disease, low potassium/magnesium and QT-prolonging or serotonergic co-medications. Do not describe these as common feline reactions. [10]

Longer use, kidney and liver disease

A single-dose SC study in 20 healthy geriatric, 20 CKD and 20 liver-disease cats found reduced clearance in the liver group, without a significant clearance difference between CKD and healthy geriatric cats. Neither automatic dose reduction nor guaranteed safety in CKD follows from this. Consider increased exposure with liver disease; single-dose data cannot quantify months-long adverse effects. Monitor constipation, intake and the underlying illness. [5]

4. Metoclopramide — also a prokinetic

Its role includes delayed gastric emptying and reduced GI motility; benefit should not be assumed for every cause of vomiting.

Feline study

In a randomised crossover trial in eight healthy cats, 0.5 mg/kg SC every 8 h for 2 days before assessment accelerated solid-meal gastric emptying; no adverse effects were observed. This short healthy-cat trial does not establish chronic-disease or long-term safety. [6]

Short-term precautions

Excitation and disorientation can occur. [1] Watch for tremors or abnormal behaviour and exclude intestinal obstruction before treatment. Renal failure may warrant dose reduction, but precise feline adjustment evidence is limited; owners should not automatically halve the dose. [7]

Long-term neurological risk: distinguish species

Human labels warn of tardive dyskinesia related to cumulative exposure. The human 12-week restriction is not a validated feline safety window. [11] The feline study reviewed here cannot estimate months-long movement-disorder incidence. Reassess the indication and benefit; contact the clinic before another dose if new neurological signs develop.

5. Mirtazapine — appetite and antiemetic support

Primarily used to stimulate appetite, it also has feline antiemetic evidence. Evaluate oral and transdermal formulations separately.

Oral evidence versus the ointment label

A crossover trial in 11 stable CKD cats used 1.88 mg/cat orally every 48 h for 3 weeks, improving appetite and weight and reducing vomiting. This small study cannot cover all unstable or advanced CKD cases. [8] The US Mirataz 2% regimen is 2 mg/cat transdermally daily for 14 days. Kidney/liver disease warrants prescription review; do not transfer oral intervals directly to ointments. [9]

Short-term effects and interactions

Vocalisation, hyperactivity, vomiting and application-site redness are reported. Kidney disease may increase exposure; liver disease also warrants caution. Mirataz is contraindicated with MAO inhibitors and within 14 days before or after them. Review other serotonergic medicines. Wear gloves and follow the label’s contact precautions. [9]

Longer use and stopping

The oral CKD trial lasted three weeks; labelled topical treatment lasts fourteen days. Neither guarantees indefinite safety. Watch for persistent behavioural or skin changes and discuss potential liver-enzyme increases. Record intake after reduction or withdrawal because appetite may fall again. [8][9]

6. Ari: a possible maropitant-associated appetite reduction

The existing care account describes Ari, then 2.8 kg with IBD, receiving 4 mg maropitant daily. Appetite response to mirtazapine declined and improved after maropitant was changed to alternate days. This is a reasonable signal for suspected drug intolerance and clinical review.

The reported feline half-life, accumulation and anorexia reports make the possibility plausible, but do not establish causation in Ari. [12][2]

💡

Distinguish a possible reaction from a proven mechanism. Improvement after reducing exposure is informative. Without drug concentrations and control of IBD activity, pain, constipation, diet and other medicines, accumulation-induced appetite suppression remains unconfirmed. The literature reviewed did not establish direct blockade of mirtazapine’s appetite effect by maropitant in cats.

Considering possible maropitant-associated appetite loss in an individual cat is appropriate; recommending alternate-day treatment for every cat is not. Record intake, vomiting, activity and medication timing for veterinary assessment of dose, interval or alternatives.

7. Monitoring during repeated treatment

Define the goal: less vomiting, less nausea, greater intake or improved gastric emptying?
Daily records: formulation, amount, time, vomiting, food intake, stool and behavioural changes.
At review: weight trend, underlying disease, all medicines and appropriate kidney/liver/electrolyte tests; ECG where individual risk warrants it.
Set a review date: lack of response or new symptoms should prompt reassessment rather than automatic attribution to long-term drug toxicity.

🩺

Breathing difficulty, facial swelling, collapse or seizures require immediate care. Contact the clinic for repeated vomiting, severe abdominal pain, inability to retain water or persistent food refusal. Antiemetics and appetite stimulants must not delay nutritional support.

Keep medication, food and vomiting records together

Care records help describe timing; correlation alone does not diagnose a drug reaction.

Open care diary Blood test analysis

Research and prescribing information

Evidence checked 2026-09-18. Feline trials, consensus, US veterinary labels and human warnings are distinguished. Limited long-term evidence means neither zero risk nor that every long-term prescription is inappropriate.

아카이브 홈